Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Today Montana.
Press releases published on August 7, 2025
Bluejay Diagnostics Provides Second Quarter Business and Corporate Update
GlobeNewswire
·
August 7, 2025
ACTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced financial results for the quarter …
VitalHub Reports Second Quarter 2025 Results
GlobeNewswire
·
August 7, 2025
Annual Recurring Revenue (ARR)(1) up 55% YoY to $79.6 million Total Revenue up 47% YoY to $23.9 million Adjusted EBITDA(1) up 50% YoY to $6.3 million TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “ …
Lifeward to Report Second Quarter Financial Results on August 14, 2025
GlobeNewswire
·
August 7, 2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or …
Nova Leap Health Corp. Posts Record Q2 2025 Results
GlobeNewswire
·
August 7, 2025
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Aug. 07, 2025 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing home health care organization, is …
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 7, 2025
– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of $238 million – – Conference call today at 5:00 …
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
August 7, 2025
– On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 – – Expanded breadth of preclinical data across pipeline, including STRO-006 and dual-payload ADCs – – Entered research collaboration with …
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
August 7, 2025
Recent positive recommendation by the Independent Data Monitoring Committee (“IDMC”) to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis Event-driven final analysis focused on disease-free survival …
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
GlobeNewswire
·
August 7, 2025
New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence Planning Vonaprument Selected by EMA as One of ~20 PRIME Development Programs in the Pilot Vonaprument Has …
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates
GlobeNewswire
·
August 7, 2025
WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates. Momentum …
Globus Medical Reports Second Quarter 2025 Results
GlobeNewswire
·
August 7, 2025
AUDUBON, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2025. Worldwide net sales were $745.3 million, an increase …
Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference
GlobeNewswire
·
August 7, 2025
DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will participate in a fireside chat at the …
AMN Healthcare Announces Second Quarter 2025 Results
GlobeNewswire
·
August 7, 2025
Quarterly revenue of $658 million and Adjusted EBITDA of $58.3 million; GAAP loss of ($3.02)/share and adjusted EPS of $0.30 DALLAS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent …
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 7, 2025
- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) - - CX-2051 Phase 1 dose expansions on track for data update in Q1 2026. Phase 2 …
TerrAscend Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
Net Revenue totaled $65 million and Gross Profit Margin was 51.1% from continuing operations, excluding Michigan 12th consecutive quarter of positive Cash Flow from continuing operations and 8th consecutive quarter of positive Free Cash Flow¹ Announced …
Biodesix Announces Second Quarter 2025 Results and Highlights
GlobeNewswire
·
August 7, 2025
Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. …
Apyx Medical Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 7, 2025
CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”) today announced that on August 4, 2025, Apyx granted a nonstatuatory stock option to purchase 100,000 shares of common stock to John …
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 7, 2025
-- Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance; Maintains Commitment to Mid-Term Outlook -- -- Nine New Programs Signed with New Customers During Fiscal 2025, Reflecting Growth into Modalities Beyond the Company's Traditional …
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire
·
August 7, 2025
Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3 ReDiscover-2 trial in Q2 Approximately $657 million in cash …
INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes
GlobeNewswire
·
August 7, 2025
BOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its …
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
GlobeNewswire
·
August 7, 2025
CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated Ozuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study ongoing; …